Repeat doses of the intrathecal antisense oligonucleotide nusinersen in children with infantile-onset spinal muscular atrophy (SMA) continue to demonstrate safety, according to early data from the phase III SHINE extension study, bringing considerable hope to the SMA community.
Individuals who have failed between two and four preventive therapies for episodic migraine may derive benefit from a once-a-month dose of erenumab, according to results of the phase IIIb LIBERTY* study.
The oral CGRP* receptor antagonist ubrogepant significantly reduced headache pain and bothersome migraine-associated symptom of a single-attack, acute migraine, according to the ACHIEVE** I study presented at AAN 2018.
High intake of fish enriched with omega-3 polyunsaturated fatty acids (PUFAs) combined with fish oil supplements were associated with a lower risk of developing multiple sclerosis (MS), according to the MS Sunshine Study presented at the AAN 2018 Annual Meeting.
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.
Invasive fungal infections, particularly those caused by Candida species, are common in hospitalized, immunocompromised, or critically ill patients and are associated with considerable morbidity and mortality.